The success of targeted therapies for cancer is undisputed; strong preclinical evidence has
resulted in the approval of several new agents for cancer treatment. The type I insulin-like …

Preclinical evidence that targeting the insulin-like growth factor receptor (IGF-IR) is effective
in cancer treatment has been accumulating for almost two decades. Efforts to develop drugs …

Research conducted over the past two decades has shown the importance of the type 1
insulin-like growth factor receptor (IGF1R) in tumorigenesis, metastasis, and resistance to …

The family of insulin/insulin-like growth factor (IGF) receptors regulates many crucial aspects
of cellular and whole-organism physiology. Evidence that targeting these receptors may be …

The insulin-like growth factor 1 receptor (IGF-1R) and its associated signalling system has
provoked considerable interest over recent years as a novel therapeutic target in cancer. A …

Insulin like growth factor receptor (IGF-1R) targeting became one of the most investigated
areas in anticancer drug development during the last decade. Strategies aiming to block IGF …

The insulin-like growth factor I receptor (IGF-IR) pathway plays a major role in cancer
growth, tumor cell survival and resistance to therapy. Ancillary evidence that targeting the …

The insulin-like growth factor (IGF) family and the IGF-1 receptor (IGF-1R) play an important
role in cancer. This intricate and complex signaling pathway provides many opportunities for …

The insulin-like growth factor-I receptor (IGF-IR) was first cloned in 1986. Since then, intense
work has defined classic phosphorelays activated via the IGF-IR, which regulate cell …

The importance of insulin-like growth factor 1 receptor (IGF-1R) signalling in malignant
behaviour of tumour cells is well established. Currently, development of drugs targeting the …